{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:25:17Z","timestamp":1793114717270,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.xops.2024.100527","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T03:13:51Z","timestamp":1712632431000},"page":"100527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-4942","authenticated-orcid":false,"given":"Sunil","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip P.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrinda","family":"Hershberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William Z.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie J.","family":"Bakri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario A.","family":"Paggiarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2024.100527_bib1","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the global burden of disease study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.xops.2024.100527_bib2","first-page":"905","article-title":"Current and future anti-VEGF agents for neovascular age-related macular degeneration","volume":"13","author":"Kaiser","year":"2021","journal-title":"J\u00a0Exp Pharmacol"},{"key":"10.1016\/j.xops.2024.100527_bib3","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/bph.15459","article-title":"Emerging therapies and their delivery for treating age-related macular degeneration","volume":"179","author":"Thomas","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xops.2024.100527_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4068\/cmj.2023.59.3.143","article-title":"Mechanistic insight into age-related macular degeneration (AMD): anatomy, epidemiology, genetics, pathogenesis, prevention, implications, and treatment strategies to pace AMD management","volume":"59","author":"Amini","year":"2023","journal-title":"Chonnam Med J"},{"key":"10.1016\/j.xops.2024.100527_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2022","journal-title":"Genes Dis"},{"key":"10.1016\/j.xops.2024.100527_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.943915","article-title":"Application and mechanism of anti-VEGF drugs in age-related macular degeneration","volume":"10","author":"Song","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.xops.2024.100527_bib7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2024.100527_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12886-021-02055-6","article-title":"Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study","volume":"21","author":"Corazza","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.xops.2024.100527_bib9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","article-title":"Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: clinical outcomes in 130 247 eyes","volume":"6","author":"Ciulla","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100527_bib10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100527_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000502747","article-title":"Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset","volume":"243","author":"Mon\u00e9s","year":"2020","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.xops.2024.100527_bib12","first-page":"294","article-title":"Current best clinical practices\u2014management of neovascular AMD","volume":"1","author":"Brown","year":"2017","journal-title":"J\u00a0Vitreoretin Dis"},{"key":"10.1016\/j.xops.2024.100527_bib13","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.2147\/OPTH.S325763","article-title":"Importance of treatment duration: unmasking barriers and discovering the reasons for undertreatment of anti-VEGF agents in neovascular age-related macular degeneration","volume":"15","author":"Sobolewska","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2024.100527_bib14","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.37765\/ajmc.2020.43435","article-title":"Wet age-related macular degeneration: treatment advances to reduce the injection burden","volume":"26","author":"Baumal","year":"2020","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.xops.2024.100527_bib15","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1038\/s41598-022-06362-w","article-title":"A\u00a0model to quantify the influence of treatment patterns and optimize outcomes in nAMD","volume":"12","author":"Ziemssen","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2024.100527_bib16","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.3390\/ijms23169424","article-title":"Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review","volume":"23","author":"Liberski","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xops.2024.100527_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2014.05.014","article-title":"Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries","volume":"158","author":"Lad","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100527_bib18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3928\/23258160-20220819-02","article-title":"Long-term visual outcomes in exudative age-related macular degeneration patients with unanticipated gaps in therapy","volume":"53","author":"Bui","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.xops.2024.100527_bib19","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.ajo.2011.09.025","article-title":"Disparities in eye care utilization among the United States adults with visual impairment: findings from the behavioral risk factor surveillance system 2006-2009","volume":"154","author":"Chou","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100527_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41433-021-01591-1","article-title":"Intravitreal treatment for geographic atrophy: coming soon to a patient near you?","volume":"36","author":"Dinah","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2024.100527_bib21","first-page":"2436","article-title":"New and innovative treatments for neovascular age-related macular degeneration (nAMD)","volume":"10","author":"Patel","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.xops.2024.100527_bib22","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","article-title":"Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents","volume":"138","author":"Evans","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2024.100527_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/IAE.0000000000003349","article-title":"Effect of retinal thickness variability on visual outcomes and fluid persistence in neovascular age-related macular degeneration: a post hoc analysis of the HAWK and HARRIER studies","volume":"42","author":"Dugel","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100527_bib24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bjophthalmol-2020-316511","article-title":"APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration","volume":"105","author":"Cohen","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100527_bib25","series-title":"ASRS 2023 Preferences and Trends Membership Survey","year":"2023"},{"key":"10.1016\/j.xops.2024.100527_bib26","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.xops.2024.100527_bib27","article-title":"The effect of CM082, an oral tyrosine kinase inhibitor, on experimental choroidal neovascularization in rats","volume":"2017","author":"Ren","year":"2017","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.xops.2024.100527_bib28","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/biom10121673","article-title":"Structural basis for vascular endothelial growth factor receptor activation and implications for disease therapy","volume":"10","author":"Shaik","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.xops.2024.100527_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40942-020-00250-z","article-title":"The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye","volume":"6","author":"Nguyen","year":"2020","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.xops.2024.100527_bib30","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1172\/JCI84871","article-title":"Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation","volume":"126","author":"Kim","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.xops.2024.100527_bib31","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xops.2024.100527_bib32","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0740","article-title":"Phase I, first-in-human, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of vorolanib in patients with advanced solid tumors","volume":"24","author":"Bendell","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.xops.2024.100527_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-022-04406-6","article-title":"Phase 1b trial of anti-VEGF\/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors","volume":"89","author":"Bagegni","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xops.2024.100527_bib34","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s10637-021-01093-7","article-title":"Vorolanib (X-82), an oral anti-VEGFR\/PDGFR\/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study","volume":"39","author":"Pedersen","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.xops.2024.100527_bib35","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/1759-7714.13430","article-title":"CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in\u00a0vitro and in\u00a0vivo","volume":"11","author":"Zhang","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.xops.2024.100527_bib36","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jamaophthalmol.2017.1571","article-title":"Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 dose-escalation study","volume":"135","author":"Jackson","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2024.100527_bib37","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2217\/cer-2018-0058","article-title":"The economic and humanistic burden of patients in receipt of current available therapies for nAMD","volume":"7","author":"Jaffe","year":"2018","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.xops.2024.100527_bib38","unstructured":"Dang S, Bansal M, Khanna S, Durrani A. Economic benefit of higher durability anti-VEGF agents in the treatment of neovascular macular degeneration. Presented at: American Society of Retina Specialists Annual Meeting; July 28 to August 1, 2023; Seattle, WA."},{"key":"10.1016\/j.xops.2024.100527_bib39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jcjo.2021.06.004","article-title":"Macular thickness fluctuation in neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor","volume":"57","author":"Chen","year":"2022","journal-title":"Can J Ophthalmol"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524000630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524000630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T23:57:21Z","timestamp":1726703841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914524000630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666914524000630"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2024.100527","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2024.100527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100527"}}